Wave 9 funding is being launched in collaboration and with financial support and guidance from the US Agency for International Development (USAID) and additional support from Global Affairs Canada.
Three priority areas:
1. Reduce pre-treatment loss to follow up for people with DR-TB.
2. Implementation of all oral DR-TB treatment regimens.
3. Improving treatment adherence and outcomes for people with DR-TB.
Utilize This Offer
Applicants are encouraged to consider the use of technology, innovative models, as well as other bold strategies to improve linkages to treatment, increasing the number of people started on all-oral regimens, or improve the treatment success of people initiating DR-TB treatments. Coordination with national partners will be critical for successful applicants as no financial support for second-line drugs will be provided through the TB REACH grants.
Applicants submitting proposals in this wave must be local, non-governmental organizations from USAID TB priority countries: Afghanistan, Bangladesh, Myanmar, Cambodia, Democratic Republic of Congo, Ethiopia, India, Indonesia, Kenya, Kyrgyzstan, Malawi, Mozambique, Nigeria, Pakistan, Philippines, South Africa, Tajikistan, Tanzania, Uganda, Ukraine, Uzbekistan, Vietnam, Zambia, and Zimbabwe.
All awarded projects will have a grant ceiling of USD 600,000.
Stage 1 Proposals will be accepted until 17:00 Geneva time, March 5, 2021.
All proposals without exception, must be submitted through the online submission platform.
For Wave 9, we will employ a two-stage process with an independent Proposal Review Committee selecting a group of applicants in April to continue to Stage 2 of the application process.
Final funding decisions are targeted to be made by mid-July
For more information, please visit https://lnkd.in/eMAYDHt